Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera’s proprietary drug candidates are designed to modulate Toll-like Receptors, the body’s first line of immune defense. Idera’s pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances.
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)’s Financial Overview
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) declined -5.59% yesterday to close its trading session at $1.69. The company has 1 year Price Target of $5. Idera Pharmaceuticals, Inc. has 52-Week high of $4.42 and 52-Week Low of $1.19. The stock touched its 52-Week High on Dec 8, 2015 and 52-Week Low on May 10, 2016. The stock traded with the volume of 1.02 Million shares yesterday. The firm shows the market capitalization of $249.58 Million.
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $-0.1/share against the analyst consensus estimate of $-0.12/share. The difference between the actual and expected EPS is $0.02 a share with a surprise factor of 16.7%.
The firm is trading with SMA20 of -1.62 Percent, SMA50 of -14.42 Percent and SMA200 of -6.97 percent. Idera Pharmaceuticals, Inc. has P/S value of 226.89 while its P/B value stands at 4.12. Similarly, the company has Return on Assets of -68.4 percent, Return on Equity of -76.7 percent and Return on Investment of 0 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 0 percent respectively.
Many brokerage firms are involved in issuing their ratings on Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). On 6-Jan-16 Wedbush Initiated Idera Pharmaceuticals, Inc. Stock to Outperform. Another firm also rated the stock on 15-Jun-15 where JP Morgan Initiated the stock to Overweight.
The Stock currently has Analyst’ mean Recommendation of 1.8 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 2 analysts offering 12-month price forecasts for Idera Pharmaceuticals Inc have a median target of 5.00, with a high estimate of 6.00 and a low estimate of 4.00. The median estimate represents a +195.86% increase from the last price of 1.69.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
Verizon Communications Inc. (NYSE:VZ)
Verizon Communications, formed by the merger of Bell Atlantic and GTE, is one of the world’s leading providers of high-growth communications services. Verizon companies are the largest providers of wireline and wireless communications in the United States. Verizon is also the world’s largest provider of print and on-line directory information.
Verizon Communications Inc. (NYSE:VZ)’s Financial Outlook
The 20 analysts offering 12-month price forecasts for Verizon have a median target of 53.00, with a high estimate of 60.00 and a low estimate of 47.00. The median estimate represents a +6.21% increase from the last price of 49.90.
Verizon Communications Inc. is expected* to report earnings on 01/24/2017 before market open. The report will be for the fiscal Quarter ending Dec 2016. According to Zacks Investment Research, based on 13 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.9. The reported EPS for the same quarter last year was $0.89.
According to Zacks Investment Research, Verizon Communications Inc. has a Consensus Recommendation of 2.52. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock fell -2.08% and closed its last trading session at $49.9. The company has the market capitalization of $203.42 Billion. The stock has 52-week high of $56.95 and 52-Week low of $43.79. The firm touched its 52-Week high on Jul 5, 2016 and 52-Week low on Jan 20, 2016. The company has volume of 20.68 Million shares. The company has a total of 4.08 Billion shares outstanding.
Verizon Communications Inc. (NYSE:VZ) in the last quarter reported its actual EPS of $1.01/share where the analyst estimated EPS was $0.99/share. The difference between the actual and Estimated EPS is $0.02. This shows a surprise factor of 2 percent.
The company has YTD performance of 12.83 percent. Beta for Verizon Communications Inc. stands at 0.4 while its ATR (average true range) is 0.78. The company has Weekly Volatility of 1.58%% and Monthly Volatility of 1.61%%.
Verizon Communications Inc. has distance from 20-day Simple Moving Average (SMA20) of 3.63%, Distance from 50-Day Simple Moving Average of 1.14 percent and Distance from 200-Day Simple Moving Average of -2.31%.
The Company currently has ROA (Return on Assets) of 5.8 percent, Return on Equity (ROE) of 75 Percent and Return on Investment (ROI) of 18.4% with Gross margin of 59.5 percent and Operating & Profit margin of 22.5% and 11% respectively.